DBV Technologies (DBVT) Share-based Compensation (2020 - 2026)
DBV Technologies (DBVT) posted Share-based Compensation of $3.7 million for Q2 2026, up 60.87% sequentially from $2.3 million in Q1 2026, and up 208.33% YoY from $1.2 million in Q2 2025.
DBV Technologies (DBVT) Share-based Compensation (2020 - 2026) Analysis & Trends
DBV Technologies has reported Share-based Compensation for 7 years, with the latest figure at $3.7 million in Q2 2026.
- Quarterly Share-based Compensation rose 208.33% year-over-year to $3.7 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $8.5 million (up 110.23% YoY) and the FY2025 annual result came in at $5.4 million, up 16.6% from the prior year.
- Share-based Compensation improved to $3.7 million in Q2 2026 per DBVT's latest filing, from $2.3 million in the prior quarter.
- Over five years, Share-based Compensation peaked at $3.7 million in Q2 2026 and troughed at -$453000.0 in Q4 2024.
- A 5-year average of $1.5 million and a median of $1.6 million in 2024 frame the typical range for Share-based Compensation.
- The sharpest annual moves came in 2024 and 2025: Share-based Compensation sank 137.16% in 2024, then soared 524.72% in 2025.
- Over 5 years, Share-based Compensation stood at $1.6 million in 2022, then decreased by 24.29% to $1.2 million in 2023, then sank by 137.16% to -$453000.0 in 2024, then jumped by 524.72% to $1.9 million in 2025, then soared by 92.31% to $3.7 million in 2026.
- According to Business Quant data, Share-based Compensation over the past three periods registered $3.7 million, $2.3 million, and $1.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 277.20 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 137.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 590,899.88 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 86.63 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 41.25 Mn |
| 10 | DBV Technologies | 6.08 Bn | 5.90 Bn | - | 3.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 3.70 Mn |
| Jun 30, 2026 | 3.70 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Mar 31, 2026 | 2.30 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Dec 31, 2025 | 1.92 Mn |
| Sep 30, 2025 | 563,000.00 |
| Sep 30, 2025 | 563,000.00 |
| Jun 30, 2025 | 1.20 Mn |
| Jun 30, 2025 | 1.20 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Mar 31, 2025 | 1.70 Mn |
| Dec 31, 2024 | -453,000.00 |
| Dec 31, 2024 | -453,000.00 |
| Sep 30, 2024 | 1.59 Mn |
| Sep 30, 2024 | 1.59 Mn |
| Jun 30, 2024 | 1.53 Mn |
| Jun 30, 2024 | 1.53 Mn |
| Mar 31, 2024 | 1.96 Mn |
| Mar 31, 2024 | 1.96 Mn |